Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials
Background: Clopidogrel low response (CLR) is an independent risk factor of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), and intensified antiplatelet treatments (IAT) guided by platelet function assays might overcome laboratory CLR. However, whether IAT improves...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2016-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=8;spage=984;epage=991;aulast=Xu |
id |
doaj-9765a9d2dad543729a574b693001791d |
---|---|
record_format |
Article |
spelling |
doaj-9765a9d2dad543729a574b693001791d2020-11-25T00:44:04ZengWolters KluwerChinese Medical Journal0366-69992016-01-01129898499110.4103/0366-6999.179786Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled TrialsLei XuXiao-Wei HuShu-Hua ZhangJi-Min LiHui ZhuKe XuJun ChenChun-Jian LiBackground: Clopidogrel low response (CLR) is an independent risk factor of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), and intensified antiplatelet treatments (IAT) guided by platelet function assays might overcome laboratory CLR. However, whether IAT improves clinical outcomes is controversial. Methods: Relevant trials were identified in PubMed, the Cochrane Library, and the Chinese Medical Journal Network databases from their establishment to September 9, 2014. Trials were screened using predefined inclusion criteria. Conventional meta-analysis and cumulative meta-analysis were performed using the Review Manager 5.0 and STATA 12.0 software programs. Results: Thirteen randomized controlled trials involving 5111 patients with CLR were recruited. During a follow-up period of 1–12 months, the incidences of cardiovascular (CV) death, nonfatal myocardial infarction (MI), and stent thrombosis were significantly lower in the IAT arm than in the conventional antiplatelet treatment arm (relative risk [RR] = 0.45, 95% confidence interval [CI]: 0.36–0.57, P < 0.000,01), whereas bleeding was similar between the two arms (RR = 1.05, 95% CI: 0.86–1.27, P = 0.65). Conclusions: IAT guided by platelet function assays reduces the risk of CV death, nonfatal MI, and stent thrombosis (ST) without an increased risk of bleeding in patients undergoing PCI and with CLR.http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=8;spage=984;epage=991;aulast=XuCoronary Artery Disease; Individualized Medicine; Platelet Aggregation Inhibitor; Platelet Function Test |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lei Xu Xiao-Wei Hu Shu-Hua Zhang Ji-Min Li Hui Zhu Ke Xu Jun Chen Chun-Jian Li |
spellingShingle |
Lei Xu Xiao-Wei Hu Shu-Hua Zhang Ji-Min Li Hui Zhu Ke Xu Jun Chen Chun-Jian Li Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials Chinese Medical Journal Coronary Artery Disease; Individualized Medicine; Platelet Aggregation Inhibitor; Platelet Function Test |
author_facet |
Lei Xu Xiao-Wei Hu Shu-Hua Zhang Ji-Min Li Hui Zhu Ke Xu Jun Chen Chun-Jian Li |
author_sort |
Lei Xu |
title |
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials |
title_short |
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials |
title_full |
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials |
title_fullStr |
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials |
title_full_unstemmed |
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials |
title_sort |
intensified antiplatelet treatment reduces major cardiac events in patients with clopidogrel low response: a meta-analysis of randomized controlled trials |
publisher |
Wolters Kluwer |
series |
Chinese Medical Journal |
issn |
0366-6999 |
publishDate |
2016-01-01 |
description |
Background: Clopidogrel low response (CLR) is an independent risk factor of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), and intensified antiplatelet treatments (IAT) guided by platelet function assays might overcome laboratory CLR. However, whether IAT improves clinical outcomes is controversial.
Methods: Relevant trials were identified in PubMed, the Cochrane Library, and the Chinese Medical Journal Network databases from their establishment to September 9, 2014. Trials were screened using predefined inclusion criteria. Conventional meta-analysis and cumulative meta-analysis were performed using the Review Manager 5.0 and STATA 12.0 software programs.
Results: Thirteen randomized controlled trials involving 5111 patients with CLR were recruited. During a follow-up period of 1–12 months, the incidences of cardiovascular (CV) death, nonfatal myocardial infarction (MI), and stent thrombosis were significantly lower in the IAT arm than in the conventional antiplatelet treatment arm (relative risk [RR] = 0.45, 95% confidence interval [CI]: 0.36–0.57, P < 0.000,01), whereas bleeding was similar between the two arms (RR = 1.05, 95% CI: 0.86–1.27, P = 0.65).
Conclusions: IAT guided by platelet function assays reduces the risk of CV death, nonfatal MI, and stent thrombosis (ST) without an increased risk of bleeding in patients undergoing PCI and with CLR. |
topic |
Coronary Artery Disease; Individualized Medicine; Platelet Aggregation Inhibitor; Platelet Function Test |
url |
http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=8;spage=984;epage=991;aulast=Xu |
work_keys_str_mv |
AT leixu intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT xiaoweihu intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT shuhuazhang intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT jiminli intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT huizhu intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT kexu intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT junchen intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials AT chunjianli intensifiedantiplatelettreatmentreducesmajorcardiaceventsinpatientswithclopidogrellowresponseametaanalysisofrandomizedcontrolledtrials |
_version_ |
1725276803903258624 |